Oddifact

Executive Summary

Oddifact is a San Francisco-based AI-driven biotechnology company founded in 2020, dedicated to discovering and developing new treatments for rare diseases. The company leverages its proprietary artificial intelligence platform to analyze existing molecules and scientific data, aiming to create regulatory-ready therapeutic program packages for partners to advance through clinical development. By focusing on rare diseases, Oddifact addresses a significant unmet medical need where traditional drug development is often economically unviable. The AI platform enables efficient repurposing and optimization of known compounds, potentially reducing the time and cost of bringing therapies to patients. As a private, early-stage company, Oddifact has not disclosed funding or valuation, but its model aligns with the growing trend of AI in biopharma. The company's success hinges on forming strategic partnerships and demonstrating preclinical proof-of-concept for its lead programs. While the rare disease space offers high-impact opportunities, the path to commercialization is long and fraught with regulatory and scientific risks. Oddifact's ability to attract collaborators and secure funding will be critical in the near term.

Upcoming Catalysts (preview)

• H2 2026Announcement of first partnership or licensing deal40% success
• Q1 2027Publication of preclinical validation data for lead program50% success
• H1 2027Series A or significant funding round35% success